articleTop 1% cited

Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

Transplantation · 2009 · Vol. 87(2) · pp. 233–242

Francesco Paolo Schena✉(University of Bari Aldo Moro)M.D. PascoeJosefina Alberú(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán)María del Carmen RialRainer OberbauerDaniel C. Brennan(Washington University in St. Louis)Josep M. CampistolLorraine C. Racusen(Johns Hopkins Medicine)Martin S. PolinskyRobert Goldberg-AlbertsHui‐Hua LiJoseph A. ScarolaJohn F. Neylan

View via DOI Publisher page

Abstract

At 2 years, SRL conversion among patients with baseline GFR more than 40 mL/min was associated with excellent patient and graft survival, no difference in BCAR, increased urinary protein excretion, and a lower incidence of malignancy compared with CNI continuation. Superior renal function was observed among patients who remained on SRL through 12 to 24 months, particularly in the subgroup of patients with baseline GFR more than 40 mL/min and UPr/Cr less than or equal to 0.11.

Renal Transplantation Outcomes and Treatments Neurological Complications and Syndromes Polyomavirus and related diseasesCalcineurinUrologyMedicineRenal functionSirolimusCreatinineTransplantationPost-hoc analysisCohortTacrolimus

MeSH terms

AdolescentAdultAgedBiopsyDrug Therapy, CombinationFemaleGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsMaleMiddle AgedNeoplasmsProspective Studies

Citations

574

FWCI

35.60

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients